Individual therapy management improves treatment success

Increasing understanding of the pathogenetic relationships of renal cell carcinoma has contributed to the development of new drugs. These specifically interfere with the VEGF, PDGF and mTOR signaling pathways. In recent years, therapies have also been developed that target the immune system to fight tumors. Where are we at mRCC today? What do the current guidelines say?